The inventions relate to medical microbiology, and more particularly to vaccines against bacterial and fungal causative agents of bronchial and pulmonary diseases, as well as to methods for manufacturing same and to methods of treatment and prophylaxis, and can be used for the treatment and prophylaxis of local and systemic, acute and chronic diseases of bacterial and fungal origin in children and adults. The present vaccine contains strains of Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Staphylococcus haemolyticus, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus viridians, Enterococcus faecalis, Enterococcus faecium, Enterococcus durans, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae, Proteus vulgaris, Proteus mirabilis, Citrobacter freundii, Alcaligenes faecalis, Morganella morganii, Pseudomonas aeruginosa, Pseudomonas alcaligenes, Candida albicans, Candida krusei, Candida glabrata, giving a total of no less than 20 species of bacteria and three species of Candida fungi, including not less than 38 strains of bacteria and five strains of fungi of the genus Candida, specifically: Staphylococcus aureus - 5, Staphylococcus haemolyticus - 3, Streptococcus pyogenes - 4, Streptococcus pneumonia - 2, Streptococcus viridians - 1, Enterococcus faecalis - 3, Enterococcus faecium - 1, Enterococcus durans - 1, Escherichia coli - 3, Klebsiella pneumonia - 2, Klebsiella oxytoca - 1, Enterobacter aerogenes - 2, Enterobacter cloacae - 1, Proteus vulgaris - 1, Proteus mirabilis - 1, Citrobacter freundii - 1, Alcaligenes faecalis - 1, Morganella morganii - 1, Pseudomonas aeruginosa - 3, Pseudomonas alcaligenes - 1, Candida albicans - 2, Candida krusei - 2, Candida glabrata - 1, isolated in the case of different acute and chronic inflammatory diseases of bacterial and fungal origin.L'invention se rapporte au domaine de la microbiologie médicale et concerne notamment des vaccins contre les excitateurs bactériens et fongiques d'affec
